Locally Advanced Pancreatic Adenocarcinoma: Where Are We and Where Are We Going?

被引：0

作者：

Chang, Bryan W. ^{[1
]}

Saif, Muhammad Wasif ^{[2
,3
]}

机构：

[1] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06510 USA

[2] Columbia Univ Coll Phys & Surg, Div Hematol & Oncol, New York, NY 10023 USA

[3] Herbert Irving Canc Ctr, New York, NY 10023 USA

来源：

JOURNAL OF THE PANCREAS | 2011年 / 12卷 / 02期

关键词：

bevacizumab; erlotinib; Fluorouracil; gemcitabine; oxaliplatin; Pancreatic Neoplasms; Radiotherapy;

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Eight abstracts highlighting the continued evolution of the management of locally advanced pancreatic cancer were presented at the 2011 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (Abstracts #195, #239, #259, #281, #287, #305, #307, #324). These studies address key issues including the role of novel targeted therapies, what chemotherapy regimen should be used in conjunction with radiotherapy, and whether locally advanced pancreatic cancer can be managed with chemotherapy alone.

引用

页码：101 / 105

页数：5

共 37 条

[1]

ANDERSON S, 2010, J CLIN ONCOL S, V28

[2] Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma:: Results of a feasibility study [J].

André, T ;

Balosso, J ;

Louvet, C ;

Hannoun, L ;

Houry, S ;

Huguier, M ;

Colonna, M ;

Lotz, JP ;

De Gramont, A ;

Bellaïche, A ;

Parc, R ;

Touboul, E ;

Izrael, V .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 46 (04) :903-911

[3]

Ben-Josef E, 2009, J CLIN ONCOL, V27

[4]

Bloomston M, 2011, J CLIN ONCOL S4, V29

[5] Radiotherapy and continuous infusion 5-fluorouracil in patients with nonresectable pancreatic carcinoma [J].

Boz, G ;

De Paoli, A ;

Innocente, R ;

Rossi, C ;

Tosolini, G ;

Pederzoli, P ;

Talamini, R ;

Trovò, MG .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 51 (03) :736-740

[6] Phase I trial of the human immunodeficiency virus protease inhibitor Nelfinavir and chemoradiation for locally advanced pancreatic cancer [J].

Brunner, Thomas B. ;

Geiger, Matthias ;

Grabenbauer, Gerhard G. ;

Lang-Welzenbach, Marga ;

Mantoni, Tine S. ;

Cavallaro, Alexander ;

Sauer, Rolf ;

Hohenberger, Werner ;

McKenna, W. Gillies .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (16) :2699-2706

[7]

Chang KJ, 2009, J CLIN ONCOL, V27

[8] Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer.: Definitive results of the 2000-01 FFCD/SFRO study [J].

Chauffert, B. ;

Mornex, F. ;

Bonnetain, F. ;

Rougier, P. ;

Mariette, C. ;

Bouche, O. ;

Bosset, J. F. ;

Aparicio, T. ;

Mineur, L. ;

Azzedine, A. ;

Hammel, P. ;

Butel, J. ;

Stremsdoerfer, N. ;

Maingon, P. ;

Bedenne, L. .

ANNALS OF ONCOLOGY, 2008, 19 (09) :1592-1599

[9] Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by Erlotinib (Tarceva) [J].

Chinnaiyan, P ;

Huang, SM ;

Vallabhaneni, G ;

Armstrong, E ;

Varambally, S ;

Tomlins, SA ;

Chinnaiyan, AM ;

Harari, PM .

CANCER RESEARCH, 2005, 65 (08) :3328-3335

[10]

CONROY T, 2010, J CLIN ONCOL S, V28

← 1 2 3 4 →